Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stille ABOSTO:STIL -2.56%100 EV-to-EBIT is 18.80 as of Aug. 01, 2026, which is 11% above its 10-year median of 16.99. GuruFocus rates OSTO:STIL with a GF Score™ of 100/100 and a GF Value™ of kr256.14 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 467 Medical Devices & Instruments companies, Stille AB ranks worse than 51.61% on this metric.
The historical rank and industry rank for Stille AB's EV-to-EBIT or its related term are showing as below:
OSTO:STIL'
s EV-to-EBIT Range Over the Past 10 Years
Min: 7.63 Med: 16.99 Max: 52.84
Current: 18.8
During the past 13 years, the highest EV-to-EBIT of Stille AB was 52.84. The lowest was 7.63. And the median was 16.99.
OSTO:STIL's EV-to-EBIT is ranked worse than 51.61% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 18.66
vs OSTO:STIL: 18.80
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Stille AB's Enterprise Value for the quarter that ended in Jun. 2026 was kr2,177.8 Mil.
Stille AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr109.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stille AB EV-to-EBIT Related Terms
Stille AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Stille AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:STIL vs ISRG, BDX, MDLN: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Stille AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stille AB EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stille AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Stille AB's EV-to-EBIT falls into.
Stille AB's current Enterprise Value is kr2,053.3 Mil.
Stille AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr109.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stille AB (OSTO:STIL) has a EV-to-EBIT of 18.80 as of Aug. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Stille AB and its competitors. This is 11% above median its historical median of 16.99. Over the past decade, Stille AB's EV-to-EBIT has ranged from 7.63 to 52.84. According to the industry distribution chart, Stille AB ranks #241 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 51.6%.
Is Stille AB's EV-to-EBIT too high?
Stille AB's current EV-to-EBIT of 18.80 is 11% above median its 10-year median of 16.99. Over the past 10 years, this metric has ranged from a low of 7.63 to a high of 52.84. The Medical Devices & Instruments industry median EV-to-EBIT is 18.66. Stille AB's value of 18.80 is 0.8% above this industry median. Based on the distribution chart, Stille AB ranks #241 out of 467 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Stille AB has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stille AB's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Stille AB ranks #241 out of 467 companies for EV-to-EBIT. This places Stille AB in the lower half of its industry. The industry median EV-to-EBIT is 18.66. Stille AB's value of 18.80 is 0.8% above this benchmark. Historically, Stille AB's own EV-to-EBIT has ranged from 7.63 to 52.84 over the past decade. While the company's 10-year median is 16.99 vs. the industry median of 18.66, Stille AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.66, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stille AB's current EV-to-EBIT of 18.80 is 0.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Stille AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stille AB's current EV-to-EBIT is 18.80, which is 11% above median its own 10-year median of 16.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stille AB stock overvalued right now?
Based on GuruFocus' analysis, Stille AB (OSTO:STIL) is currently considered Modestly Undervalued. The stock's GF Value™ is kr256.14, compared to a current price of kr228.00 — trading 11% below its estimated fair value. The current EV-to-EBIT is 18.80, which is 11% above median its 10-year median of 16.99 and 0.8% above the Medical Devices & Instruments industry median of 18.66. Stille AB's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Stille AB (OSTO:STIL), the current EV-to-EBIT is 18.80 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stille AB (OSTO:STIL) Overvalued in 2026?
Based on GuruFocus' analysis, Stille AB stock appears to be undervalued.
The current stock price of kr228.00 is trading 11% below its estimated GF Value™ of kr256.14.
GuruFocus considers Stille AB to be Modestly Undervalued.
Key valuation signals for OSTO:STIL:
EV-to-EBIT: 18.80 (11% above median its 10-year median of 16.99)
GF Value™: kr256.14 vs. price of kr228.00 (11% below fair value)
Industry Position: 0.8% above the Medical Devices & Instruments median (#241 of 467)
No single metric tells the full story. See the OSTO:STIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stille AB manufactures and distributes medical devices. Its products include surgical equipment such as Surgical Scissors, Forceps, Curettes, Raspatories, Elevators, c-arm tables and instrument care education, among others.
100GF Score
Get the complete analysis for OSTO:STIL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:STIL has been successfully added to your 
